Researchers caution that Gray’s good results must still be considered preliminary — it’s early days yet, and this is just one patient. Much is still unknown, including whether the treatment will make a lasting improvement in Gray’s health and whether it will be safe in the long run for her and other patients.

Researchers caution that Gray’s good results must still be considered preliminary — it’s early days yet, and this is just one patient. Much is still unknown, including whether the treatment will make a lasting improvement in Gray’s health and whether it will be safe in the long run for her and other patients.